IceCure Highlights ProSense® Cryoablation at the 2026 ASBrS Annual Meeting Amidst Rising Commercial Momentum in the U.S.

IceCure Showcases ProSense® at the 2026 ASBrS Annual Meeting

In a significant display of innovation in breast cancer treatment, IceCure Medical recently showcased its ProSense® Cryoablation technology at the 2026 American Society of Breast Surgeons (ASBrS) Annual Meeting held in Seattle from April 29 to May 3. This marked a pivotal moment for the company as it continues to gain traction in the U.S. market following its recent FDA clearance.

ProSense® is unique as it represents the only FDA-approved minimally invasive treatment specifically designed for low-risk breast cancer patients, aligning perfectly with the emerging treatment trend of de-escalation in breast cancer care. The ASBrS, a leading professional organization, has now included cryoablation as a recommended treatment modality in its updated Resource Guide for low-risk patients, further solidifying the relevance of IceCure’s technology.

During the conference, IceCure sponsored an engaging symposium titled "Unlocking De-Escalation Cryoablation for Breast Cancer," led by prominent figures in the field. Notable attendees included Dr. Richard Fine from West Cancer Center, Dr. Lauren Kopicky from Cleveland Clinic, Dr. Michael Sabel from the University of Michigan, and Dr. Robert Ward from the Warren Alpert Medical School at Brown University, all of whom shared invaluable insights on the effectiveness and real-world usability of the ProSense® system.

According to Eyal Shamir, CEO of IceCure, the ongoing sales growth of ProSense® reflects the positive reception and increasing demand among healthcare professionals. "Our presence at ASBrS 2026 is crucial for enhancing the visibility of our cryoablation system among breast surgeons and medical teams worldwide," he stated. Shamir also highlighted the recent endorsement of cryoablation in major treatment guidelines as a groundbreaking affirmation that could elevate its status as a standard care option for suitable patients.

Dr. Lauren Kopicky added that ProSense® provides an innovative avenue in treating older adults (70 years and above) with low-risk breast cancer. The procedure, performed under local anesthesia during a brief office visit, minimizes recovery time and maintains aesthetic integrity, offering patients a compelling alternative to traditional surgical interventions.

The ProSense® Cryoablation System utilizes cutting-edge liquid nitrogen technology to destroy tumor cells by freezing, effectively targeting both benign and malignant lesions. The system's design is particularly suited for outpatient procedures, enhancing the overall efficiency of breast cancer treatment regimens.

In preliminary unaudited forecasts, IceCure anticipates that revenue generated from ProSense® systems and cryoprobes in the first quarter of 2026 will reflect an increase of over 30% when compared to the same period in 2025, further emphasizing the commercial momentum behind their innovative solutions.

With the endorsement of cryoablation in the ASBrS Resource Guide, there is an ongoing commitment toward fine-tuning patient selection, imaging techniques, and follow-up procedures, reinforcing safety and efficacy.

A New Era for Breast Cancer Treatment

IceCure’s ProSense® is not just a product but a paradigm shift in the way healthcare providers approach low-risk breast cancer. By opting for cryoablation, patients can expect a less invasive procedure without sacrificing treatment quality—a concern paramount among aging populations or those seeking alternatives to more traditional approaches.

As clinical data continues to emerge supporting the safety and effectiveness of this technology, IceCure stands poised to play a significant role in reshaping the landscape of breast cancer treatment. With the burgeoning acceptance found within the surgical community and robust evidence supporting their practices, ProSense® is paving the way for a more patient-centric approach to managing breast cancer.

In conclusion, IceCure Medical is not only enhancing treatment options for breast cancer patients but also sparking necessary dialogues about reducing treatment burdens while maintaining effectiveness in critical oncology care. The momentum witnessed at the ASBrS Annual Meeting may just be the beginning of a transformative journey in cancer therapy.